Bristol-Myers Squibb Says FDA-Approved ORENCIA is Available for Adults with Moderate to Severe Rheumatoid Arthritis

Bristol-Myers Squibb Company

disclosed Wednesday the commercial launch of the FDA-approved ORENCIA ClickJectTM Autoinjector, a new self-administered autoinjector for adults with moderate to severe rheumatoid arthritis (RA). According to the company, the ORENCIA ClickJect delivers 125 mg of subcutaneous (SC) ORENCIA with push button operation, as well as, injection confirmation that might reduce the possibility of user errors. Bristol-Myers Squibb Head of U.S. Commercial, Chris Boerner, said, "Today's launch of the ORENCIA ClickJect is an example of our continued commitment to offering patients with moderate to severe rheumatoid arthritis a treatment option that may be appropriate for them, now available as an autoinjector." He continued to add,"This approval offers more options for healthcare providers and members of the arthritis community to consider when selecting the optimal treatment and administration option for each individual." The company stated that ORENCIA ClickJect has an ergonomic design apart from non-slip grip enabling control by dexterity-compromised patients. The company added that ORENCIA is the only RA biologic offering three administration options, i.e., IV infusion, prefilled syringe and Autoinjector. In the pre-market trading on Wednesday, the stock traded 0.04 percent up.